The news that two potential Ebola cases in Brazil have been ruled out is being hailed as a triumph for the UK-funded screening programme. Cynics like myself cannot help but view it through a different lens. Two individuals presented with symptoms. They were tested. Negatives came back. The system worked? Let us examine the fiscal ledger.
First, the cost. The UK government, through its Department of Health and Social Care, has allocated significant sums to these screening initiatives. The precise figure is opaque for operational security, but a reasonable estimate for the Brazil programme alone runs into the millions of pounds. This includes training, equipment, and personnel deployment. The return on that investment? Two false alarms. One might argue that the programme provides reassurance, a public good. But what is the price of reassurance? In bond markets, we call that a yield premium. Here, the yield appears negative.
Second, the opportunity cost. Every pound spent on Ebola screening in Brazil is a pound not spent on other health priorities. The UK faces an NHS waiting list crisis, a cost-of-living squeeze, and a fiscal deficit that exceeds 5% of GDP. Treasury officials would be wise to question whether these funds could have been better allocated to reducing hospital backlogs or easing inflationary pressures on households. Instead, we have a speculative disease screening programme in a country with limited direct travel links to Ebola-affected regions.
Third, the risk of moral hazard. By funding screening abroad, the government may create a dependency. Brazil, a G20 economy, has its own fiscal resources. If the UK perpetually underwrites its health security, what incentive does Brasilia have to invest in its own epidemiological surveillance? This is the classic free-rider problem in public finance. UK taxpayers cannot be the world's underwriters for every emerging health threat.
Yet the official narrative is one of success. Health Secretary Stephen Barclay described the programme as 'a world-class defence against infectious diseases.' Such language is designed to appeal to sentiment rather than financial prudence. Let us apply the market test: if these screening programmes were a publicly traded company, would you buy the stock? The revenue stream is government subsidies, not productive activity. The liabilities are open-ended. The track record is two scares and no actual cases. I would short that equity.
The broader context is a pattern of government spending on 'preparedness' that lacks rigorous cost-effectiveness analysis. Since the pandemic, the UK has poured billions into vaccine stockpiles, genome sequencing, and global health security. While some of this is necessary, the marginal bang for the buck diminishes rapidly. The Treasury should demand a net present value calculation of each programme. If the expected benefit, discounted for probability, does not exceed the cost, the market would reject it. Government should be no different.
In the end, the Brazil episode is a parable of modern fiscal policy: high hopes, considerable expenditure, and a modest outcome. The media will celebrate it as a vindication. But this editor will remember that the bottom line shows a net loss. UK fiscal space is not infinite. Every false alarm funded by taxpayer pounds is a real cost to someone else's health, education, or infrastructure. That is the opportunity cost we cannot afford to forget.
